Prognostic factors for chemotherapy induced nausea and vomiting

European Journal of Pharmacology

Volumn 722, Issue 1, 2014, Pages 192-196

  Warr, David ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Cancer; Chemotherapy; Emesis; Prognostic

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; NALOXONE; NEUROKININ 1 RECEPTOR ANTAGONIST; OLANZAPINE; ONDANSETRON; OPIATE DERIVATIVE; SEROTONIN 3 ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

AGE; ALCOHOL CONSUMPTION; ANXIETY; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; EVIDENCE BASED MEDICINE; EXPECTATION; GENDER; HUMAN; MODEL; MOTION SICKNESS; PHARMACOGENOMICS; PRACTICE GUIDELINE; PREDICTION; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

CANCER; CHEMOTHERAPY; EMESIS; PROGNOSTIC;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MODELS, STATISTICAL; NAUSEA; PROGNOSIS; RISK FACTORS; VOMITING;

EID: 84892839486     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.10.015     Document Type: Review

References (33)

1. M. Aapro, A. Molassiotis, M. Dicato, I. Pelaez, A. Rodriguez-Lescure, D. Pastorelli, L. Ma, T. Burke, A. Gu, P. Gascon, and F. Roila The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER) Ann. Oncol. 23 2012 1986 1992
2. E. Basch, A.A. Prestrud, P.J. Hesketh, M.G. Kris, P.C. Feyer, M.R. Somerfield, M. Chesney, R.A. Clark-Snow, A.M. Flaherty, B. Freundlich, G. Morrow, K.V. Rao, R.N. Schwartz, and G.H. Lyman Antiemetics: American Society of Clinical Oncology clinical practice guideline update J. Clin. Oncol. 29 2011 4189 4198
3. T.M. Beck, P.J. Hesketh, S. Madajewicz, R.M. Navari, K. Pendergrass, E.P. Lester, J.A. Kish, W.K. Murphy, J.D. Hainsworth, and D.R. Gandara et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting J. Clin. Oncol. 10 1992 1969 1975
4. R. de Wit, J. Herrstedt, B. Rapoport, A.D. Carides, G. Carides, M. Elmer, C. Schmidt, J.K. Evans, and K.J. Horgan Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy J. Clin. Oncol. 21 2003 4105 4111
5. G. Dranitsaris, N. Bouganim, C. Milano, L. Vandermeer, S. Dent, P. Wheatley-Price, J. Laporte, K.A. Oxborough, and M. Clemons Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting J. Support. Oncol. 2012
6. R.J. Gralla, R. de Wit, J. Herrstedt, A.D. Carides, J. Ianus, J. Guoguang-Ma, J.K. Evans, and K.J. Horgan Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials Cancer 104 2005 864 868
7. J. Herrstedt, H.B. Muss, D.G. Warr, P.J. Hesketh, P.D. Eisenberg, H. Raftopoulos, S.M. Grunberg, M. Gabriel, A. Rodgers, C.M. Hustad, K.J. Horgan, and F. Skobieranda Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy Cancer 104 2005 1548 1555
8. P.J. Hesketh, M. Aapro, J.C. Street, and A.D. Carides Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy Support. Care Cancer 18 2010 1171 1177
9. P.J. Hesketh, S.M. Grunberg, J. Herrstedt, R. de Wit, R.J. Gralla, A.D. Carides, A. Taylor, J.K. Evans, and K.J. Horgan Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response Support. Care Cancer 14 2006 354 360
10. P.J. Hesketh, M.G. Kris, S.M. Grunberg, T. Beck, J.D. Hainsworth, G. Harker, M.S. Aapro, D. Gandara, and C.M. Lindley Proposal for classifying the acute emetogenicity of cancer chemotherapy J. Clin. Oncol. 15 1997 103 109
11. K. Jordan, F. Jahn, P. Jahn, T. Behlendorf, A. Stein, J. Ruessel, T. Kegel, and H.J. Schmoll The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination Bone Marrow Transplant. 46 2011 784 789
12. R. Kaiser, O. Sezer, A. Papies, S. Bauer, C. Schelenz, P.B. Tremblay, K. Possinger, I. Roots, and J. Brockmoller Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes 20 2002 2805 2811 J. Clin. Oncol. 20 2002 2805 2811
13. J. Kirkova, L. Rybicki, D. Walsh, and A. Aktas Symptom prevalence in advanced cancer: age, gender, and performance status interactions Am. J. Hosp. Palliat. Care 29 2012 139 145
14. N.L. Kobrinsky, P.B. Pruden, M.S. Cheang, M. Levitt, A.J. Bishop, and M. Tenenbein Increased nausea and vomiting induced by naloxone in patients receiving cancer chemotherapy Am. J. Pediatr. Hematol. Oncol. 10 1988 206 208
15. O.M. Koriech Fluoxetine treatment comprises the antiemetic efficacy of ondansetron in cancer patients Clin. Oncol. (R. Coll. Radiol.) 7 1995 371 372
16. M.G. Kris, R.J. Gralla, R.A. Clark, L.B. Tyson, and S. Groshen Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial Cancer 60 1987 2816 2822
17. K. Leslie, P.S. Myles, M.T. Chan, M.J. Paech, P. Peyton, A. Forbes, and D. McKenzie Risk factors for severe postoperative nausea and vomiting in a randomized trial of nitrous oxide-based vs nitrous oxide-free anaesthesia Br. J. Anaesth. 101 2008 498 505
18. O. Mir, J.P. Durand, P. Boudou-Rouquette, J. Giroux, R. Coriat, A. Cessot, S. Ropert, F. Goldwasser, and R. Gaillard Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: A case-control study Support. Care Cancer 20 2012 2235 2239
19. A. Molassiotis, B.M. Yam, H. Yung, F.Y. Chan, and T.S. Mok Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients Support. Care Cancer 10 2002 139 145
20. R.M. Navari, C.K. Nagy, and S.E. Gray The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy Support. Care Cancer: Off. J. Multinatl. Assoc. Support. Care Cancer 2013
21. D. Osoba, B. Zee, J. Pater, D. Warr, J. Latreille, and L. Kaizer Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol. 15 1997 116 123
22. J. Pater, L. Slamet, B. Zee, D. Osoba, D. Warr, and J. Rusthoven Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting Support. Care Cancer 2 1994 161 166
23. D.A. Perwitasari, H. Gelderblom, J. Atthobari, M. Mustofa, I. Dwiprahasto, J.W. Nortier, and H.J. Guchelaar Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. Int J Clin. Pharm. 33 2011 33 43
24. C. Pirri, P. Katris, J. Trotter, E. Bayliss, R. Bennett, and P. Drummond Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: A prospective, longitudinal, observational study 19 2011 Support. Care Cancer 19 2011 1549 1563
25. B.L. Rapoport, K. Jordan, J.A. Boice, A. Taylor, C. Brown, J.S. Hardwick, A. Carides, T. Webb, and H.J. Schmoll Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study Support. Care Cancer 18 2010 423 431
26. F. Roila Control of acute cisplatin-induced emesis over repeat courses of chemotherapy. Italian Group for Antiemetic Research Oncology 53 Suppl. 1 1996 65 72
27. F. Roila, M. Tonato, C. Basurto, M. Picciafuoco, S. Bracarda, D. Donati, P. Malacarne, L. Monici, F. Di Costanzo, and L. Patoia et al. Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: A study of the Italian Oncology Group for Clinical Research J Clin Oncol. 7 1989 1693 1700
28. F. Roila, J. Herrstedt, M. Aapro, R.J. Gralla, L.H. Einhorn, E. Ballatori, E. Bria, R.A. Clark-Snow, B.T. Espersen, P. Feyer, S.M. Grunberg, P.J. Hesketh, K. Jordan, M.G. Kris, E. Maranzano, A. Molassiotis, G. Morrow, I. Olver, B.L. Rapoport, C. Rittenberg, M. Saito, M. Tonato, D. Warr, and Group E.M.G.W. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference Ann. Oncol. 21 Suppl. 5 2010 v232 243
29. J.A. Roscoe, P. Bushunow, G.R. Morrow, J.T. Hickok, P.J. Kuebler, A. Jacobs, and T.K. Banerjee Patient expectation is a strong predictor of severe nausea after chemotherapy: A University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma Cancer. 101 2004 2701 2708
30. I. Sekine, Y. Segawa, K. Kubota, and T. Saeki Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis Cancer Sci. 104 2013 711 717
31. A. Shoji, M. Toda, K. Suzuki, H. Takahashi, K. Takahashi, Y. Yoshiike, T. Ogura, Y. Watanuki, H. Nishiyama, and S. Odagiri Insufficient effectiveness of 5-hydroxytryptamine-3 receptor antagonists due to oral morphine administration in patients with cisplatin-induced emesis J. Clin. Oncol. 17 1999 1926 1930
32. D.G. Warr, S.M. Grunberg, R.J. Gralla, P.J. Hesketh, F. Roila, R. Wit, A.D. Carides, A. Taylor, J.K. Evans, and K.J. Horgan The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials Eur. J. Cancer 41 2005 1278 1285
33. D.G. Warr, J.C. Street, and A.D. Carides Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy Support. Care Cancer 19 2011 807 813